GervanoRA Data Services (GDS) Projects Germany's Pharmaceutical Market is the Largest in Europe and is Expected to Reach $63.3 Billion by 2022

Monday, October 16, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

GOA, India, October 16, 2017 /PRNewswire/ --

According to a new country specific report

"GER0004CI Germany Insights: Healthcare Industry, Policies, Regulations and PESTLE Analysis" published by GervanoRA Data Services (GDS), Germany' pharmaceutical market is expected to reach $63.3 billion
by 2022.

Germany's healthcare market is the largest in Europe and fourth largest in the world. The market is expected to be driven by the robust healthcare system, strong patent policies, high healthcare expenditure and well established regulatory procedures. However, government's initiatives like AMNOG and growing generics market will hinder this growth.

Ramu Jadhav, Managing Director of life sciences at GDS commented, "Germany is the third largest medical device market in the world after the U.S. and Japan and is estimated to reach $43.9 bn by 2022. The medical device market accounts for 40% of the EU market."

Jadhav continued: "The Statutory Health Insurance (SHI) covering around 90% of the population and the government expenditure of approximately 11.3% of GDP on healthcare system, one of the highest in European countries drives the healthcare market. Germany ranks fourth globally with 1,183 patent applications submitted to the European Patent Office in the field of biotechnology and pharmaceuticals in 2015." Growing patent applications will introduce more new drugs in Germany during the forecast period and is expected to increase the patent drug market.

German government's Act of reform of medicinal products (Arzneimittelmarkt-Neuordnungsgesetz - AMNOG), a law initiated in 2011 to restructure the pharmaceutical market act as a barrier for the pharmaceutical market. The Act aims to limit the cost of pharmaceuticals and to reduce the growing drug expenditures in the public health sector. The Act hence obliges pharmaceutical companies to subject their new products to an early evaluation of their additional benefit by the Federal Joint Committee (Gemeinsamer Bundesausschuss - G-BA) after being launched on the market. The measures have not been welcomed by most drug manufacturers.

Jadhav added: "The government's drug price freezes, growing generic market and limited drug availability in the mandatory health insurance will also hinder the growth."

To read GervanoRA's Germany Insights full report, please visit:

About GervanoRA 

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we're playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.

To assist our global clients to attain their segment, sub segment specific goals, we are more enlightening them on domine specific live updates through our GervanoRA 360[o] PharmMedTech Monthly Bulletin (Monthly Report) which serve our clients with bespoke requirements without missing any live update for the particular month, as we know how valuable it is to be stayed updated with day to day dynamic industry sectors.

Recently Published Other Reports: 

1. Rheumatoid Arthritis: Global Market Analysis 2016 and Forecast 2017-2027

2. Psoriasis: Global Market Analysis 2016 and Forecast 2017-2027

3. Bronchoscopes: Global Market Analysis 2016 and Forecast 2017-2027

4. Colonoscopes: Global Market Analysis 2016 and Forecast 2017-2027

GervanoRA even provides the subscription based services like:

  • Deals and Acquisitions Database & Analytics (Only $100 per month)
  • Emerging Technologies Database & Analytics (Only $100 per month)
  • GervanoRA 360[o] PharmMedTech Monthly Bulletin (Only $100 per month)

To find out more about GervanoRA, please visit: .


India (Head Office)                          Mr. Ramu Jadhav GervanoRA Data      Services LLP                                      Verna, Goa - 403722 India                                            Ph. No. +91(0)832-2783283

United States +1(901)210-7246

United Kingdom +44-7894444092

New Zealand +64-20-4545453 <end_table>

Connect with us on LinkedIn @

SOURCE GervanoRA Data Services LLP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store